Novo Nordisk plans to submit weekly growth hormone for approval in H1
![Photo: Kevin Grønnemann](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article11298514.ece/ALTERNATES/schema-16_9/ascendis.jpg)
Novo Nordisk is planning to submit its once-weekly growth hormone deficiency (GHD) treatment for children, Sogroya, for regulatory approval in the first half of 2022, the company announces in its financial report on Wednesday.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Ascendis Pharma extends trial of growth hormone in adults
For subscribers